Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up - What's Next?

Key Points

• Daiichi Sankyo's stock price gapped up from $23.25 to $24.30 at opening, with last trading at $24.45 and a volume of 76,930 shares.
• Nomura Securities upgraded Daiichi Sankyo to a "strong-buy" rating, contributing to its overall average rating of "Strong Buy" from analysts.
• The company has a market cap of $46.02 billion and a P/E ratio of 22.92, indicating strong financial performance and stability.

Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report)'s stock price gapped up before the market opened on Thursday . The stock had previously closed at $23.25, but opened at $24.30. Daiichi Sankyo shares last traded at $24.45, with a volume of 76,930 shares trading hands.

Analysts Set New Price Targets

Separately, Nomura Securities upgraded Daiichi Sankyo to a "strong-buy" rating in a research note on Friday, June 6th. One research analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Strong Buy".

Daiichi Sankyo Stock Performance

The company has a market cap of $46.02 billion and a P/E ratio of 22.92. The firm's fifty day moving average price is $24.32 and its 200-day moving average price is $24.17. The company has a current ratio of 2.31, a quick ratio of 1.60 and a debt-to-equity ratio of 0.06.

Daiichi Sankyo Company Profile

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.